GCP
LSTA icon

GSA Capital Partners’s Lisata Therapeutics LSTA Stock Holding History

GSA Capital Partners’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-155
Closed -$59K – 2077
2015
Q1 		$59K Buy
+155
New +$84K ﹤0.01% 2050

Other funds holding LSTA

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GSA Capital Partners's LSTA Position: Q2 2015 in Review

GSA Capital Partners sold out of Lisata Therapeutics (LSTA) in Q2 2015, closing a stake of 155 shares — an estimated $59K sold.

GSA Capital Partners first reported a position in LSTA in Q1 2015 and held it in 1 quarter. The position peaked at $59K in Q1 2015. 51 funds tracked by Wall St. Rank hold LSTA as of Q2 2015.

  • GSA Capital Partners reported no remaining Lisata Therapeutics position as of Q2 2015 after selling out during the quarter.
  • GSA Capital Partners sold 155 Lisata Therapeutics shares in Q2 2015, an estimated $59K.
  • GSA Capital Partners first reported a position in Lisata Therapeutics in Q1 2015 and held it in 1 quarter.
  • GSA Capital Partners's Lisata Therapeutics position peaked at $59K in Q1 2015.
  • 51 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2015.

Based on GSA Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.